Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
0.6203
-0.0485 (-7.25%)
Delayed Quote
Updated: 11:40 AM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
October 14, 2026
From
Invivyd, Inc.
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From
Invivyd, Inc.
Via
GlobeNewswire
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
September 29, 2026
From
Invivyd, Inc.
Via
GlobeNewswire
Invivyd to Participate in Upcoming September Investor Conferences
September 08, 2026
From
Invivyd, Inc.
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
September 01, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 06, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
June 16, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine
June 09, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
June 01, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate in Upcoming Investor Events
May 27, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 14, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
May 11, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
May 07, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
April 20, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
April 09, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
April 07, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Presentation at the World Vaccine Congress Washington
March 30, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
March 05, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
March 05, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
March 02, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From
Invivyd
Via
GlobeNewswire
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
February 24, 2026
From
Invivyd
Via
GlobeNewswire
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 03, 2026
From
Invivyd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
